卵巢癌组织中PCDH8、TSLC1基因启动子甲基化状态及其与患者预后的关系

doi:10.3969/j.issn.1671-7171.2023.02.014

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1135 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨卵巢癌组织中原钙黏蛋白8(PCDH8)、肺癌抑癌基因1(TSLC1)基因启动子甲基化状态及其与患者预后的关系。【方法】回顾性分析2017年5月至2018年5月在本院行手术治疗的104例卵巢癌患者的临床资料,对所有患者术后均随访36个月,将随访期间出现病灶转移及复发、死亡的患者纳入预后不良组(n=60),余下的纳入预后良好组(n=44)。甲基化特异性聚合酶链反应(MSP)检测所有患者卵巢癌组织中PCDH8、TSLC1基因启动子甲基化状态,单因素分析和多因素分析卵巢癌患者预后不良的影响因素。【结果】预后不良组患者卵巢癌组织中PCDH8基因启动子、TSLC1基因甲基化率分别为80.00%(48/60)、58.33%(35/60),显著高于预后良好组患者的36.36%(16/44)、18.18%(8/44),差异有统计学意义(χ²=20.422、16.875,P<0.05)。预后不良组FIGO分期、淋巴结有无转移、分化程度、PCDH8基因启动子甲基化状态、TSLC1基因启动子甲基化状态与预后良好组比较,差异有统计学意义(P<0.05)。FIGO分期Ⅲ~Ⅳ期、淋巴结有转移、分化程度G₃、PCDH8基因启动子甲基化状态阳性、TSLC1基因启动子甲基化状态阳性均是卵巢癌患者预后不良的危险因素(P<0.05)。【结论】预后不良的卵巢癌患者癌组织中PCDH8、TSLC1基因启动子甲基化阳性率明显高于预后良好患者, PCDH8、TSLC1基因启动子甲基化状态与其预后显著相关,二者均可评估卵巢癌患者预后。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	王蕊
	刘阳
	邓云静

关键词 ：卵巢肿瘤/病理学, 卵巢肿瘤/遗传学, 细胞粘附分子1, 启动区,遗传学, DNA甲基化

Abstract：【Objective】To investigate the methylation status of the promoter of PCDH8 and TSLC1 genes in ovarian cancer tissue and relationship with prognosis. 【Methods】The clinical data of 104 patients with ovarian cancer who underwent surgical treatment in our hospital from May 2017 to May 2018 were retrospectively analyzed. All patients were followed up for 36 months after surgery. The patients with metastasis,recurrence and death during the follow-up period were set as the poor prognosis group (n=60),and the rest were the good prognosis group (n=44). Methylation-specific polymerase chain reaction (MSP) was used to detect the methylation status of PCDH8 and TSLC1 gene promoters in ovarian cancer tissues of all patients. Univariate analysis and multivariate analysis were used to analyze the factors affecting the poor prognosis of ovarian cancer patients.【Results】The methylation rates of PCDH8 gene promoter and TSLC1 gene promoter in ovarian cancer tissue of patients with poor prognosis were 80.00% (48/60) and 58.33% (35/60),respectively,which were significantly higher than those of patients with good prognosis 36.36% (16/44) and 18.18% (8/44),respectively. The difference was statistically significant(χ²=20.422、16.875,P<0.05). There were statistically significant differences in FIGO stage,lymph node metastasis,degree of differentiation,PCDH8 gene promoter methylation status,and TSLC1 gene promoter methylation status between the poor prognosis group and the good prognosis group (P<0.05). FIGO stage Ⅲ~Ⅳ,lymph node metastasis,degree of differentiation G₃,positive PCDH8 and TSLC1 gene promoter methylation status were all risk factors for the poor prognosis of ovarian cancer patients (P<0.05).【Conclusion】The positive rates of both PCDH8 and TSLC1 gene promoter methylation in the cancer tissue of patients with poor prognosis are significantly higher than those of patients with good prognosis. The methylation status of both PCDH8 and TSLC1 gene promoters is significantly correlated with the prognosis and can be used to evaluate the prognosis of patients with ovarian cancer.

Key words： Ovarian Neoplasms/PA Ovarian Neoplasms/GE Cell Adhesion Molecule-1 Promoter Regions, Genetic DNA Methylation

收稿日期: 2022-03-09

中图分类号:

R737.31

通讯作者: *E-mail:479963891@qq.com

引用本文:

王蕊, 刘阳, 邓云静. 卵巢癌组织中PCDH8、TSLC1基因启动子甲基化状态及其与患者预后的关系[J]. 医学临床研究, 2023, 40(2): 209-212.
WANG Rui, LIU Yang, DNEG Yun-jing. Methylation Status of PCDH8 and TSLC1 Gene Promoters in Ovarian Cancer Tissue and Relationship with Prognosis. JOURNAL OF CLINICAL RESEARCH, 2023, 40(2): 209-212.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2023.02.014 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2023/V40/I2/209

[1] 葛倩倩.多西他赛联合异环磷酰胺对卵巢癌 CAOV3 细胞 cyclinD1 及GADD153表达的影响[J].医学临床研究,2019,36(10):1893-1895.
[2] ZHANG P,WANG H,WANG J,et al. Association between protocadherin 8 promoter hypermethylation and the pathological status of prostate cancer[J].Oncol Lett ,2017,14(2):1657-1664.
[3] 陈现亮,吴义娟.MTA1和TSLC1表达与结肠腺瘤癌变相关性研究[J].中华肿瘤防治杂志,2017,24(13):871-874.
[4] 林仲秋,谢玲玲,李晶. FIGO 2013卵巢癌、输卵管癌、腹膜癌新分期解读[J].中国实用妇科与产科杂志,2013,29(12):921-923.
[5] 李巍,崔恒,冯捷,等. 卵巢癌诊断的研究进展[J].中华妇产科杂志,2005,40(7):496-498.
[6] 薛凤霞,赵敬. 复发性卵巢癌的诊断[J].中国实用妇科与产科杂志,2005,21(7):385-386.
[7] LARSEN L K,LIND G E,GULDBERG P,et al. DNA-methylation-based detection of urological cancer in urine:overview of biomarkers and considerations on biomarker design,source of DNA,and detection technologies[J].Int J Mol Sci,2019,20(11):2657.
[8] 张丹杰,李少民,姜建涛,等. 胃癌中PCDH8基因启动子甲基化状态及其临床意义[J].现代肿瘤医学,2018,26(15):2417-2421.
[9] 陈素云,赵志新,褚邦勇. 肝癌癌组织PCDH8、RIZ1基因甲基化状态及临床意义[J].重庆医学,2020,49(24):4075-4079.
[10] YANSHI L,CHUAN L,ZHIHAI W,et al. Expression of protocadherin8:Function as a tumor suppressor in hypopharyngeal carcinoma [J].Cancer Biomark,2018,22(3):495-502.
[11] 冶正财,安钰,李宏亮,等. 食管鳞癌组织中TSLC1基因启动子甲基化状态检测的临床意义[J].现代肿瘤医学,2018,26(15):2368-2370.
[12] 吴晓,庄轶轩,陈炯玉,等. 肺癌肿瘤抑制因子1在雌激素受体、孕激素受体不同表达乳腺癌患者中的临床意义[J].转化医学杂志,2017,6(5):261-265.
[13] 王碧荣,袁高乐,梁启廉,等. 肺癌肿瘤抑制物1对人大肠癌细胞株HT29增殖与凋亡的影响[J].中华实验外科杂志,2018,35(2):234-237.
[14] 刘玉红,高菊荣,王琰. 口腔鳞状细胞癌中TSLC1基因启动子甲基化状态检测的临床意义[J].现代肿瘤医学,2017,25(21):3423-3425.